Penumbra (PEN) Stock Forecast & Price Target → Alex's 'Next Magnificent Seven' Stocks (From The Oxford Club) (Ad) Free PEN Stock Alerts $190.87 +2.83 (+1.50%) (As of 06/4/2024 ET) Add Compare Share Share Analyst ForecastsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Penumbra - Analysts' Recommendations and Stock Price Forecast (2024)How MarketBeat Calculates Price Target and Consensus RatingMarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Consensus Rating Moderate BuyBased on 10 Analyst Ratings Consensus Price Target $300.6457.51% UpsideHigh Forecast$376.00Average Forecast$300.64Low Forecast$240.00 TypeCurrent Forecast6/5/23 to 6/4/241 Month Ago5/6/23 to 5/5/243 Months Ago3/7/23 to 3/6/241 Year Ago6/5/22 to 6/5/23Consensus RatingModerate BuyModerate BuyModerate BuyModerate BuyStrong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)0 Strong Buy rating(s)Buy7 Buy rating(s)7 Buy rating(s)7 Buy rating(s)10 Buy rating(s)Hold3 Hold rating(s)2 Hold rating(s)3 Hold rating(s)1 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)Consensus Price Target$300.64$304.45$305.36$307.91Forecasted Upside57.51% Upside20.24% Upside17.64% Upside20.81% Upside Get Penumbra Upgrade and Downgrade Alerts Sign-up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter. Email Address Ad The Oxford ClubAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.Watch Alex's "Next Magnificent Seven" presentation now. PEN Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History PEN Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Penumbra Stock vs. The CompetitionTypePenumbraMedical CompaniesS&P 500Consensus Rating Score2.702.692.49Consensus RatingModerate BuyModerate BuyHoldPredicted Upside57.51% Upside826.84% Upside10.91% UpsideNews Sentiment RatingPositive NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame * Start Date * End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails5/8/2024Canaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$284.00 ➝ $272.00+34.79%5/8/2024Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetOverweight ➝ Overweight$290.00 ➝ $260.00+27.25%5/8/2024Needham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingHold3/22/2024Truist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$290.00 ➝ $280.00+23.04%2/23/2024Royal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ Outperform$289.00+19.05%2/23/2024JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeOverweight ➝ Neutral$284.00 ➝ $250.00-4.81% Get the Latest News and Ratings for PEN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter. 11/3/2023Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetEqual Weight ➝ Equal Weight$265.00 ➝ $240.00+21.07%10/2/2023CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower TargetBuy ➝ Buy$390.00 ➝ $320.00+35.16%8/2/2023Wells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetOverweight ➝ Overweight$320.00 ➝ $337.00+21.92%8/2/2023BTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy rating Lower Target$351.00 ➝ $308.00+3.24%7/18/2023Robert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageOutperform$375.00+19.22%6/26/2023Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost Target$325.00 ➝ $376.00+13.18%5/3/202358.comSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingMaintains10/12/2022Jefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Initiated CoverageBuy$230.00+27.86%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 11:01 PM ET. PEN Frequently Asked Questions What is Penumbra's stock forecast and purchase recommendation? According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Penumbra is $300.64, with a high forecast of $376.00 and a low forecast of $240.00. The consensus rating for Penumbra stock is Moderate Buy based on the current 3 hold ratings and 7 buy ratings for PEN. Learn more on PEN's analyst rating history. Do Wall Street analysts like Penumbra more than its competitors? Analysts like Penumbra more than other "medical" companies. The consensus rating score for Penumbra is 2.70 while the average consensus rating score for "medical" companies is 2.69. Learn more on how PEN compares to other companies. Does Penumbra's stock price have much upside? According to analysts, Penumbra's stock has a predicted upside of 21.21% based on their 12-month stock forecasts. What analysts cover Penumbra? Penumbra has been rated by research analysts at Canaccord Genuity Group, Needham & Company LLC, Piper Sandler, and Truist Financial in the past 90 days. Stock Forecasts and Research Tools Related Companies: West Pharmaceutical Services Stock Forecast Baxter International Stock Forecast Shockwave Medical Stock Forecast Insulet Stock Forecast Solventum Stock Forecast Teleflex Stock Forecast Globus Medical Stock Forecast Glaukos Stock Forecast Inspire Medical Systems Stock Forecast Merit Medical Systems Stock Forecast Today's Ratings: U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks: Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools: Stock Ratings by Company Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NYSE:PEN) was last updated on 6/4/2024 by MarketBeat.com Staff From Our PartnersWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club| SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry| SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press| SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro| SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings| SponsoredWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace| SponsoredThe Worst is Yet to Come…Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepar...Porter & Company| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Penumbra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Penumbra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.